Navigation Links
Next-Generation Drug-Device Combinations Provide Innovative Delivery Methods for the Growing Biologics Market
Date:3/4/2013

FALLS CHURCH, Va., March 4, 2013 /PRNewswire/ -- One of the most critical challenges confronting the pharmaceutical industry is developing patient-friendly delivery systems for the growing biologics market, which currently totals $150 billion worldwide.  As the population ages, and the incidence rate of chronic indications rises globally, the market for biologics is expected to increase at a rate of nearly 10 percent annually. Biologic therapies typically require parenteral delivery due to their large size; however, injections are often painful for the patient, have a high risk of needle-stick injury, and require administration by a healthcare professional.  Consequently, there is a need to develop patient-friendly delivery methods for biologics that are convenient, safe, and increase patient compliance. Drug companies are actively seeking novel devices to make it easier for patients to self-administer drugs. By combining the drug formulation with a device, companies also have the opportunity to differentiate existing drugs as well as novel products in the pipeline.

Arina Paoli , Global Marketing Communications Manager for 3M, explains that the growing biologics market is driving the need for innovated delivery devices including microneedles. "We believe microneedle technologies will play a key role in the growth of the biologics market. We are seeing companies explore our MTS microneedle technologies to treat chronic conditions, such as rheumatoid arthritis, because this new delivery system has the potential to improve compliance and be easier to administer for both patients and caregivers," states Paoli.

To address these critical needs and identify business opportunities in this rapidly growing sector, Technology Catalysts International has launched a new Technology and Business Review on Next- Generation Self-Administered Drug-Device Combinations: New Technologies and Business Opportunities. This report focuses on the following leading delivery systems that will play a transformational role in optimizing delivery of biologics and promoting self-administration and enhanced patient compliance:

  • Autoinjectors and pen injectors
  • Prefilled syringes
  • Active transdermal devices, with a focus on microneedles
  • Inhalers

This report highlights the important regulatory approval process for drug-device combination products in the US, EU, and Japan. Important device design considerations, market trends, future applications, and challenges to developing drug-device combinations are also discussed. TCI's new report on Next-Generation Self-Administered Drug-Device Combinations will be made available online. Online features include:

  • Technology profiles updated in real time
  • A searchable database of technology profiles
  • Recent news on new product launches, licensing agreements, and collaborations

For complete report prospectus, pricing, and ordering information, please refer to:

http://www.technology-catalysts.com/reports_services/ddc.asp

About Technology Catalysts International:

Technology Catalysts International ("TCI") was founded in 1979 and provides consulting services in technology transfer and business research. The company specializes in technology licensing, technology assessment, and business intelligence with a focus on pharmaceuticals, drug delivery, consumer healthcare, and advanced materials/processes. TCI is headquartered in the US and has offices in the UK, Germany, Czech Republic, China, Korea, Japan, India, and Latin America.

Contact:

Ajay Rastogi , Vice President
Technology Catalysts International
Telephone (703) 531-0257
arastogi@technology-catalysts.com
http://www.technology-catalysts.com


'/>"/>
SOURCE Technology Catalysts International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
2. QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows
3. Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics
4. Frost & Sullivan: Next-Generation Sequencing Services is one of the Fastest Growing Markets in the Life Sciences Industry
5. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
6. MicuRx Pharmaceuticals Announces Issuance Of U.S. Patent For Its Next-Generation Antibacterial Agent
7. Remedy Informatics to Debut SpecimenTrack, Next-Generation Biorepository Software at ISBER 2012 Annual Meeting
8. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
9. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
10. HCG Injection Provider Posts Customer Testimonials on Ushcginjections.com Reviews Page
11. Nonin Medical Selected as Exclusive Provider of Cerebral/Somatic Oximetry Systems to Leading Pediatric Hospitals in Poland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 12, 2017   Divoti USA will engrave ... the standard of the latest FDA requirements, which stipulates new criteria ... Anyone in need of Medical ID jewelry such as Medical ID ... are engraved in terms of the new FDA requirements . ... Divoti offers this dark mark ...
(Date:10/11/2017)...  BioPharmX Corporation (NYSE MKT: BPMX) researchers were part ... way to use nonlinear optical imaging to confirm the ... A presentation ... how researchers from BioPharmX and the Wellman Center for ... suite of imaging techniques in what is called "Pharmacokinetic ...
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
Breaking Medicine Technology:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of ... announced today its plans to open a flagship location in Covington, LA at 401 ... Rooms To Go store next to Office Depot in the Holiday Square shopping center. ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):